Issue of options and directors dealings

 

 

 

VALIRX PLC

("ValiRx", the "Company" or the "Group")

 

Issue of options and directors dealings

 

London, UK., 9 February 2018: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, announces it has awarded options to directors and key management.  The options may be exercised at a price of 4 pence per share at any time up until 7 February 2028.

 

Name of Director	Number of Existing Options*	Option Award	Total number of Options	% of existing share capital
Oliver de Giorgio-Miller	555,000	2,750,000	3,305,000	0.8%
Dr Satu Vainikka	694,000	3,625,000	4,319,000	1.1%
Dr George Morris	597,000	3,125,000	3,722,000	0.9%
Gerry Desler	592,960	3,000,000	3,592,960	0.9%
Kevin Alexander	545,000	2,500,000	3,045,000	0.7%
Others	429,000	2,300,000	2,279,000	0.6%
Total	3,412,960	17,300,000	20,712,960	5.0%

*existing options are exercisable at a price between 43.125p - 125p

The issued share capital of the Company comprises 407,462,717 ordinary shares of 0.1 pence per shares. The table below illustrates the existing equity holdings of the directors:

Name of Director	Total number of shares	% of existing share capital
Oliver de Giorgio-Miller	59,555	0.015%
Dr Satu Vainikka	624,909	0.15%
Dr George Morris	588,287	0.14%
Gerry Desler	541,875	0.13%
Kevin Alexander	104,278	0.026%
Total	1,918,904	0.46%

 

 

*** ENDS ***

 

For more information, please contact:

 

ValiRx plc	Tel: +44 (0) 20 3008 4416 www.valirx.com
Dr Satu Vainikka, Chief Executive	Tel: +44 (0) 20 3008 4416
Tarquin Edwards, Head of Communications.	Tel: +44 (0) 7879 458 364 [email protected]
Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray/Jo Turner/Richard Nash	Tel: +44 (0) 20 7213 0880
Beaufort Securities Limited (Broker) Jon Belliss	Tel: +44 (0) 207 382 8300

 

Notes for Editors

About ValiRx

ValiRx is a biotechnology oncology focused company specialising in developing novel treatments for cancer and associated biomarkers. It aims to make a significant contribution in "precision" medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention.

The Company's business model focuses on out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value. The group is already in licensing discussions with major players in the oncology field.

ValiRx's two classes of drugs in development, which each have the potential for meeting hitherto unmet medical needs by existing methods, have worldwide patent filings and agreed commercial rights. They originate or derive from World class institutions, such as Cancer Research UK and Imperial College.

Until recently, cancer treatments relied on non-specific agents, such as chemotherapy.  With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible. New drugs in this group-such as those in ValiRx's pipeline-promise to greatly improve outcomes for cancer patients.

The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Oliver de Giorgio-Miller
2	Reason for notification
a.	Position/Status	Director
b.	Initial notification/ Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	ValiRx Plc
b.	LEI	213800VQKB9SJCQDET40
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Options over ordinary shares   ISIN: GB00BWWYSP41
b.	Nature of the transaction	Grant of options
c.	Price(s) and volume(s)
			Price(s) per share	Volume(s)
			4p	2,750,000
d.	Aggregated information   - Aggregated Volume   - Price	2,750,000   4p
e.	Date of the transaction	9 February 2018
f.	Place of the transaction	AIM

 

 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Dr Satu Vainikka
2	Reason for notification
a.	Position/Status	Director
b.	Initial notification/ Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	ValiRx Plc
b.	LEI	213800VQKB9SJCQDET40
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Options over ordinary shares   ISIN: GB00BWWYSP41
b.	Nature of the transaction	Grant of options
c.	Price(s) and volume(s)
			Price(s) per share	Volume(s)
			4p	3,625,000
d.	Aggregated information   - Aggregated Volume   - Price	3,625,000   4p
e.	Date of the transaction	9 February 2018
f.	Place of the transaction	AIM

 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Dr George Morris
2	Reason for notification
a.	Position/Status	Director
b.	Initial notification/ Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	ValiRx Plc
b.	LEI	213800VQKB9SJCQDET40
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Options over ordinary shares   ISIN: GB00BWWYSP41
b.	Nature of the transaction	Grant of options
c.	Price(s) and volume(s)
			Price(s) per share	Volume(s)
			4p	3,125,000
d.	Aggregated information   - Aggregated Volume   - Price	3,125,000   4p
e.	Date of the transaction	9 February 2018
f.	Place of the transaction	AIM

 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Gerry Desler
2	Reason for notification
a.	Position/Status	Director
b.	Initial notification/ Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	ValiRx Plc
b.	LEI	213800VQKB9SJCQDET40
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Options over ordinary shares   ISIN: GB00BWWYSP41
b.	Nature of the transaction	Grant of options
c.	Price(s) and volume(s)
			Price(s) per share	Volume(s)
			4p	3,000,000
d.	Aggregated information   - Aggregated Volume   - Price	3,000,000   4p
e.	Date of the transaction	9 February 2018
f.	Place of the transaction	AIM

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Kevin Alexander
2	Reason for notification
a.	Position/Status	Director
b.	Initial notification/ Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	ValiRx Plc
b.	LEI	213800VQKB9SJCQDET40
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Options over ordinary shares   ISIN: GB00BWWYSP41
b.	Nature of the transaction	Grant of options
c.	Price(s) and volume(s)
			Price(s) per share	Volume(s)
			4p	2,500,000
d.	Aggregated information   - Aggregated Volume   - Price	2,500,000   4p
e.	Date of the transaction	9 February 2018
f.	Place of the transaction	AIM